Monoclonal Antibody Therapy Approved for Adults with Newly Diagnosed Light-chain Amyloidosis
Daratumumab and hyaluronidase-fihj is now indicated as part of a combination therapy for the potentially fatal condition that can...
Progress Against Cancer
Daratumumab and hyaluronidase-fihj is now indicated as part of a combination therapy for the potentially fatal condition that can...
FDA expands selumetinib approval to include treatment of adults with inoperable plexiform neurofibromas. The U.S. Food and Drug Administration...
The FDA approved pertuzumab-dpzb for interchangeable use with pertuzumab. The U.S. Food and Drug Administration (FDA) has approved pertuzumab-dpzb...
The FDA has approved the menin inhibitor ziftomenib for adults with relapsed or refractory acute myeloid leukemias harboring susceptible...
The FDA approved daratumumab and hyaluronidase-fihj for adults with smoldering multiple myeloma that has a high risk of progression. ...
The FDA has approved the menin inhibitor revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1...
The FDA approved the BCMA-targeted antibody-drug conjugate belantamab mafodotin-blmf as part of a combination therapy for adults with refractory...
The FDA approved cemiplimab-rwlc as an adjuvant therapy for patients with cutaneous squamous cell carcinoma at high risk of...
The FDA has approved the DNA-damaging agent in combination with immunotherapy for patients whose cancers have not progressed after...